Storing Tirzepatide: Best Practices
40 Citas PubMedRevisado por EspecialistasCertificado GMPÚltima Revisión: mayo de 2026
⚠️ Importante: Este producto es una solución, no un polvo liofilizado. Los requisitos de almacenamiento difieren de los polvos peptídicos estándar.
❄️ Almacenamiento Refrigerado
La solución de tirzepatide debe almacenarse en refrigerador a 2°C a 8°C (36°F a 46°F). Almacenar en el envase original para proteger de la luz. No almacenar en la puerta del refrigerador para evitar fluctuaciones de temperatura.
🌡️ Excursión a Temperatura Ambiente
Los viales o plumas de dosis única pueden almacenarse sin refrigeración a temperaturas que no excedan los 30°C (86°F) durante un máximo de 21 días. Si no se utiliza dentro de este período, el producto debe descartarse. Las plumas multidosis (cuando estén disponibles) pueden tener un período de uso de hasta 30 días después del primer uso.
❄️ Congelación
NO congelar. Si la solución ha sido congelada, no debe utilizarse y debe descartarse.
🧴 Precauciones de Manipulación
La solución debe ser clara, incolora a ligeramente amarilla. No utilizar si la solución está turbia, descolorida o contiene materia particulada. Cada vial está acompañado de un Certificado de Análisis (COA) que detalla la verificación de pureza mediante RP-HPLC y Espectrometría de Masas (MS). Este producto es solo para uso en investigación (RUO).
Expert Observation
“Estudios en Animales Metabólico/Energético (Ratones, Bossi 2025): 10 nmol/kg SC diario × 4 semanas — 15,6 g de pérdida de peso (vs.”
Referencias
- Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in study subjects with Type 2 Diabetes. N Engl J Med, 385(6), 503–515, 2021.
- Min T, Bain SC. The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials. Diabetes Ther, 12(1), 143–157, 2021.
- Chavda VP, Ajabiya J, Teli D, et al. Tirzepatide, a New Era of Dual-Targeted research application for Diabetes and Obesity: A Mini-Review. Molecules, 27(13), 4315, 2022.
- U.S. FDA. MOUNJARO® (tirzepatide) Injection — Prescribing Information. FDA Access Data, 2022.
- U.S. FDA. ZEPBOUND® (tirzepatide) Injection — Prescribing Information. FDA Access Data, 2024.
- Liu QK. Mechanisms of action and experimental applications of GLP-1 and dual GIP/GLP-1 receptor agonists. Front Endocrinol, 15, 1431292, 2024.
- Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in study subjects with Type 2 Diabetes. N Engl J Med, 385(6), 503-515, 2021.
- Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the investigation of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab, 18, 3–14, 2018.
- Sun B, Willard FS, Bhavsar S, et al. Tirzepatide’s biased agonism at the GLP-1 receptor. Signal Transduction Res, 2022.
- Geisler CE, Antonellis MP, Trumbauer W, et al. Tirzepatide suppresses palatable food intake by selectively reducing preference for fat in rodents. Diabetes Obes Metab, 25(1), 56–67, 2022.
- Ghaleb J, Khouzami KK, Nassif N, et al. Unveiling Tirzepatide’s experimental Spectrum: A Dual GIP/GLP-1 Agonist Targeting Metabolic, Neurological, and Cardiovascular Health. Int J Endocrinol, 2025, 2876156, 2025.
- Liu C, et al. Tirzepatide attenuates lipopolysaccharide-induced cardiomyopathy via inhibiting TLR4/NF-κB/NLRP3 pathway. 2023.
- Fontanella RA, Ghosh P, Pesapane A, et al. Tirzepatide prevents neurodegeneration through multiple molecular pathways. J Transl Med, 22, 114, 2024.
- Rosenstock J, Wysham C, Frías JP, et al. Efficacy and tolerability of tirzepatide in study subjects with type 2 diabetes (SURPASS-1). Lancet, 398(10295), 143–155, 2021.
- Del Prato S, Kahn SE, Pavo I, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). Lancet, 398(10313), 1811–1824, 2021.
- Bossi AC, et al. Animal research reveals metabolic differences between tirzepatide and semaglutide. 2025.
- Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N Engl J Med, 391(4), 299–310, 2024.
- European Medicines Agency. Mounjaro (tirzepatide) — Summary of Product Characteristics. EMA, 2023.
- Rosenstock J, Wysham C, Frías JP, et al. Efficacy and tolerability of tirzepatide in study subjects with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet, 398(10295), 143–155, 2021.
- Nicholls SJ, Pavo I, Bhatt DL, et al. Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes. N Engl J Med, 393, 2409–2420, 2025.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the investigation of Obesity. N Engl J Med, 387(3), 205–216, 2022.
- Jastreboff AM, le Roux CW, Stefanski A, et al. Tirzepatide for Obesity research application and Diabetes Prevention. N Engl J Med, 392(10), 958–971, 2025.
- Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the investigation of Obesity. N Engl J Med, 393(1), 26–36, 2025.
- Packer M, Zile MR, Kramer CM, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med, 392(5), 427–437, 2025.
- Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the investigation of Obstructive Sleep Apnea and Obesity. N Engl J Med, 391, 1193–1205, 2024.
- Yang Y, et al. Tirzepatide demonstrates neuroprotective effects in APP/PS1 Alzheimer’s disease model. 2024.
- Heerspink HJL, et al. Kidney outcomes with tirzepatide vs insulin glargine (SURPASS-4 exploratory analysis). Lancet Diabetes Endocrinol, 2022.
- Geisler CE, Antonellis MP, Trumbauer W, et al. Tirzepatide suppresses palatable food intake by selectively reducing preference for fat in rodents. Diabetes Obes Metab, 25(1), 56–67, 2022.
- U.S. FDA. MOUNJARO Prescribing Information — Carcinogenicity and Reproductive Toxicity Data. FDA, 2022.
- Garvey WT, Frías JP, Jastreboff AM, et al. Tirzepatide once weekly for the investigation of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet, 402(10402), 613–626, 2023.
- Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3). Nat Med, 29(11), 2909–2918, 2023.
- Aronne LJ, Sattar N, Horn DB, et al. Continued research application With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4). JAMA, 331(1), 38–48, 2024.
- Ludvik B, Giorgino F, Jódar E, et al. Once-weekly tirzepatide versus once-daily insulin degludec (SURPASS-3). Lancet, 398, 583–598, 2021.
- Dahl D, Onishi Y, Norwood P, et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine (SURPASS-5). JAMA, 327(6), 534–545, 2022.
- Rosenstock J, Frías JP, Rodbard HW, et al. Tirzepatide vs Insulin Lispro Added to Basal Insulin (SURPASS-6). JAMA, 330(17), 1631–1640, 2023.
- Inagaki N, et al. Efficacy and tolerability of tirzepatide in Japanese study subjects with type 2 diabetes (SURPASS-J-mono). Lancet Diabetes Endocrinol, 2022.
- Gao L, Lee BW, Chawla M, et al. Tirzepatide versus insulin glargine in the Asia-Pacific region (SURPASS-AP-Combo). Nat Med, 29(6), 1500–1510, 2023.
- Frías JP, Nauck MA, Van J, et al. Efficacy and tolerability of LY3298176 (tirzepatide), a novel dual GIP and GLP-1 receptor agonist: a randomised phase 2 trial. Lancet, 392(10160), 2180–2193, 2018.
- Angelopoulos N, et al. Short-term effects of low-dose tirzepatide on lipid profile, glucose homeostasis and hepatic steatosis index in adults with obesity. J Diabetes Complications, 39(12), 109181, 2025.
- Gandhi A, Parhizgar A. GLP-1 receptor agonists in Alzheimer’s and Parkinson’s disease. Front Endocrinol, 16, 1708565, 2025.
Preguntas de Investigación Relacionadas
Desea la revisión completa de la investigación?
Ver Página Completa de Investigación de Tirzepatide→SOLO PARA USO EN INVESTIGACIÓN
Este contenido se proporciona solo para fines educativos e informativos. Los productos se suministran exclusivamente para estudios in vitro y no son medicamentos, fármacos ni suplementos. No están aprobados por la FDA para prevenir, tratar o curar ninguna condición.